Rhythm Pharmaceuticals (RYTM) Competitors $62.65 -1.22 (-1.91%) As of 02:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RYTM vs. ITCI, GMAB, RDY, VTRS, MRNA, QGEN, ASND, ROIV, RVMD, and BBIOShould you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Moderna (MRNA), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Rhythm Pharmaceuticals vs. Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Viatris Moderna Qiagen Ascendis Pharma A/S Roivant Sciences Revolution Medicines BridgeBio Pharma Rhythm Pharmaceuticals (NASDAQ:RYTM) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking, risk, valuation and institutional ownership. Do institutionals and insiders believe in RYTM or ITCI? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 6.1% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better earnings and valuation, RYTM or ITCI? Intra-Cellular Therapies has higher revenue and earnings than Rhythm Pharmaceuticals. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$136.86M29.69-$184.68M-$2.81-22.73Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 Does the media prefer RYTM or ITCI? In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 8 mentions for Rhythm Pharmaceuticals and 3 mentions for Intra-Cellular Therapies. Rhythm Pharmaceuticals' average media sentiment score of 0.93 beat Intra-Cellular Therapies' score of 0.25 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intra-Cellular Therapies 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor RYTM or ITCI? Intra-Cellular Therapies received 212 more outperform votes than Rhythm Pharmaceuticals when rated by MarketBeat users. However, 68.13% of users gave Rhythm Pharmaceuticals an outperform vote while only 65.74% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformRhythm PharmaceuticalsOutperform Votes31068.13% Underperform Votes14531.87% Intra-Cellular TherapiesOutperform Votes52265.74% Underperform Votes27234.26% Is RYTM or ITCI more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-230.07% -367.36% -77.47% Intra-Cellular Therapies -14.07%-9.93%-8.38% Do analysts prefer RYTM or ITCI? Rhythm Pharmaceuticals currently has a consensus target price of $75.38, indicating a potential upside of 18.03%. Intra-Cellular Therapies has a consensus target price of $109.70, indicating a potential downside of 16.81%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Which has more volatility and risk, RYTM or ITCI? Rhythm Pharmaceuticals has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. SummaryRhythm Pharmaceuticals beats Intra-Cellular Therapies on 10 of the 18 factors compared between the two stocks. Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RYTM vs. The Competition Export to ExcelMetricRhythm PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.06B$6.55B$5.43B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-14.759.1426.8320.05Price / Sales29.69255.60392.35116.46Price / CashN/A65.8538.2534.62Price / Book22.256.546.874.61Net Income-$184.68M$143.51M$3.22B$248.19M7 Day Performance11.50%5.60%6.76%2.97%1 Month Performance5.61%10.06%13.66%16.58%1 Year Performance68.03%-0.86%18.27%8.16% Rhythm Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RYTMRhythm Pharmaceuticals3.9307 of 5 stars$62.65-1.9%$75.38+20.3%+63.9%$3.99B$136.86M-14.49140ITCIIntra-Cellular Therapies0.8696 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.3167 of 5 stars$19.93+2.9%$39.17+96.5%-31.5%$12.78B$21.64B11.451,660News CoveragePositive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories2.3513 of 5 stars$13.93+3.9%$17.00+22.1%+5.3%$11.62B$311.31B22.1724,800Positive NewsVTRSViatris2.1196 of 5 stars$8.96+2.2%$10.50+17.2%-19.8%$10.63B$14.33B-12.1137,000Trending NewsMRNAModerna4.512 of 5 stars$25.70+6.0%$53.95+109.9%-80.2%$9.94B$3.14B-2.773,900Trending NewsGap UpQGENQiagen4.0353 of 5 stars$42.92+2.5%$48.42+12.8%-3.4%$9.54B$1.98B119.526,030Positive NewsASNDAscendis Pharma A/S3.5415 of 5 stars$154.43+2.1%$216.07+39.9%+33.5%$9.42B$368.70M-21.75640Positive NewsROIVRoivant Sciences2.0126 of 5 stars$10.99+3.3%$17.50+59.2%-2.9%$7.84B$122.59M-73.26860Positive NewsRVMDRevolution Medicines4.4108 of 5 stars$41.88+3.6%$67.17+60.4%+1.1%$7.80B$742,000.00-11.67250Positive NewsBBIOBridgeBio Pharma4.6353 of 5 stars$35.68+4.4%$57.09+60.0%+14.2%$6.77B$127.42M-12.52400Insider Trade Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Viatris Competitors Moderna Competitors Qiagen Competitors Ascendis Pharma A/S Competitors Roivant Sciences Competitors Revolution Medicines Competitors BridgeBio Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RYTM) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RYTM Stock Free RYTM Stock Alerts